:format(webp)/cdn.mskdoctors.com/storage/2026/8/WyTUgPyuRTUUHCpsWkxQLHIH1zV03yj2.jpg)
Can ChondroFiller delay joint replacement?An injectable collagen scaffold called ChondroFiller recruits the patient's own repair cells to regenerate cartilage in 30–45 minutes. Clinical trials show IKDC score improvements averaging 32.4 points — nearly double the threshold for clinically significant change — when administered in early focal cartilage damage where joint space remains.An injectable collagen scaffold called ChondroFiller recruits the patient's own repair cells to regenerate cartilage in 30–45 minutes. Clinical trials show IKDC score improvements averaging 32.4 points — nearly double the threshold for clinically significant change — when administered in early focal cartilage damage where joint space remains.
:format(webp)/cdn.mskdoctors.com/storage/2026/8/IzsaocPUogYnIOJVw9huJQI13qh16Tsb.jpg)
How long osteochondral allografts lastFresh osteochondral allografts achieve approximately 82–86% graft survival at five years and roughly 70% beyond 20 years; outcomes depend substantially on patient BMI, prior knee surgery, and adherence to structured post-operative support.Fresh osteochondral allografts achieve approximately 82–86% graft survival at five years and roughly 70% beyond 20 years; outcomes depend substantially on patient BMI, prior knee surgery, and adherence to structured post-operative support.
:format(webp)/cdn.mskdoctors.com/storage/2026/8/2of3MbpwJvcJrDYn03x9VVz3ZGqDUeFf.jpg)
ChondroFiller vs hyaluronic acid for cartilage repairChondroFiller repairs focal cartilage lesions by recruiting the patient's own cells; hyaluronic acid eases broad osteoarthritis by restoring synovial fluid. These injections treat fundamentally different conditions, and selecting the wrong one offers little clinical value.ChondroFiller repairs focal cartilage lesions by recruiting the patient's own cells; hyaluronic acid eases broad osteoarthritis by restoring synovial fluid. These injections treat fundamentally different conditions, and selecting the wrong one offers little clinical value.
:format(webp)/cdn.mskdoctors.com/storage/2026/8/766rT75vrzgAcHwc9vxAXYr5JrU3PaGe.jpg)
ChondroFiller injection versus knee replacement for focal defectsChondroFiller, a gelling collagen scaffold that recruits the patient's own cells to repair cartilage, suits isolated focal defects; knee replacement addresses widespread multi-compartment osteoarthritis.ChondroFiller, a gelling collagen scaffold that recruits the patient's own cells to repair cartilage, suits isolated focal defects; knee replacement addresses widespread multi-compartment osteoarthritis.
:format(webp)/cdn.mskdoctors.com/storage/2026/8/rjdUoSXZw7DBQPxbfDpZXz3tnkbbwYXu.jpg)
Who qualifies for MACI knee surgery?Patients aged 18–55 with deep focal cartilage damage (Grade III-IV, >2 cm²) qualify for MACI if their knees are structurally sound—stable ligaments, correct alignment, no generalised osteoarthritis—and conservative treatment has failed. The procedure is two-stage, with extended rehabilitation required.Patients aged 18–55 with deep focal cartilage damage (Grade III-IV, >2 cm²) qualify for MACI if their knees are structurally sound—stable ligaments, correct alignment, no generalised osteoarthritis—and conservative treatment has failed. The procedure is two-stage, with extended rehabilitation required.
:format(webp)/cdn.mskdoctors.com/storage/2026/7/9g6eTwTAu0SFvMuWK32Dks5irUrV7k8r.jpg)
OATS for Osteochondral Lesions of the TalusLesions larger than approximately 150 mm² fail bone marrow stimulation treatment 97% of the time. OATS transplants genuine hyaline cartilage to replace the weakening fibrocartilage scar that microfracture produces in larger defects.Lesions larger than approximately 150 mm² fail bone marrow stimulation treatment 97% of the time. OATS transplants genuine hyaline cartilage to replace the weakening fibrocartilage scar that microfracture produces in larger defects.
:format(webp)/cdn.mskdoctors.com/storage/2026/7/8ilKw2XCH5pB5TWOt6kewJNVnwz4zE0V.jpg)
What the ChondroFiller evidence actually showsChondroFiller's reoperation rate of 3–8% substantially outperforms microfracture (41%) and ACI/MACI (37%), reflecting its mechanism: the scaffold supports hyaline-like cartilage repair rather than the fibrocartilage scar tissue that other approaches produce.ChondroFiller's reoperation rate of 3–8% substantially outperforms microfracture (41%) and ACI/MACI (37%), reflecting its mechanism: the scaffold supports hyaline-like cartilage repair rather than the fibrocartilage scar tissue that other approaches produce.
:format(webp)/cdn.mskdoctors.com/storage/2026/7/ETKg1ueF5BBKIau7DxGIoPsVzI5r2krh.jpg)
ChondroFiller and Arthrosamid serve different knee conditionsChondroFiller recruits progenitor cells to rebuild focal cartilage defects, whilst Arthrosamid provides permanent cushioning for diffuse osteoarthritis by integrating into the joint capsule; the choice between them follows from what MRI reveals about the damage pattern, not from symptom severity.ChondroFiller recruits progenitor cells to rebuild focal cartilage defects, whilst Arthrosamid provides permanent cushioning for diffuse osteoarthritis by integrating into the joint capsule; the choice between them follows from what MRI reveals about the damage pattern, not from symptom severity.
:format(webp)/cdn.mskdoctors.com/storage/2026/7/UY0InSBaoOinSJHR9T3qmZrV7DMIQOXA.jpg)
ChondroFiller vs PRP for focal cartilage defectsFocal cartilage defects and diffuse cartilage loss are different problems requiring different solutions. ChondroFiller, a collagen scaffold, physically occupies and stabilises focal voids, recruiting repair cells over 12–24 months. PRP releases growth factors to reduce inflammation but cannot fill a structural gap. Imaging reveals which mechanism addresses the patient's underlying…Focal cartilage defects and diffuse cartilage loss are different problems requiring different solutions. ChondroFiller, a collagen scaffold, physically occupies and stabilises focal voids, recruiting repair cells over 12–24 months. PRP releases growth factors to reduce inflammation but cannot fill a structural gap. Imaging reveals which mechanism addresses the patient's underlying problem.
:format(webp)/cdn.mskdoctors.com/storage/2026/7/nJpuPYmYxVIJuCuke5TmcJtXlcYJxImS.jpg)
ChondroFiller or Arthrosamid for your kneeChondroFiller repairs focal cartilage defects via a collagen scaffold, and Arthrosamid provides cushioning by integrating into the synovial lining — because they target different anatomical structures, the MRI scan, not patient preference, determines which injection is appropriate.ChondroFiller repairs focal cartilage defects via a collagen scaffold, and Arthrosamid provides cushioning by integrating into the synovial lining — because they target different anatomical structures, the MRI scan, not patient preference, determines which injection is appropriate.
:format(webp)/cdn.mskdoctors.com/storage/2026/6/Ftb0eLP1qk86rzkUGQIcwelqCKAR75gI.jpg)
ChondroFiller injection vs PRP for cartilage repairChondroFiller fills focal cartilage defects with a collagen scaffold; PRP modulates inflammation in diffuse wear. MRI findings, not symptoms, determine which applies.ChondroFiller fills focal cartilage defects with a collagen scaffold; PRP modulates inflammation in diffuse wear. MRI findings, not symptoms, determine which applies.
:format(webp)/cdn.mskdoctors.com/storage/2026/5/ZblwdFdi3Q4Yy8tyYSJSAsJS9CBjfOtg.jpg)
Choosing Arthrosamid knee injections for osteoarthritisArthrosamid is a single ultrasound-guided hydrogel injection for mild-to-moderate knee osteoarthritis, used when exercise, painkillers and other non-surgical care have not eased function-limiting pain. Early studies show meaningful improvement for many patients at 12 months, but evidence remains less robust than for established treatments.Arthrosamid is a single ultrasound-guided hydrogel injection for mild-to-moderate knee osteoarthritis, used when exercise, painkillers and other non-surgical care have not eased function-limiting pain. Early studies show meaningful improvement for many patients at 12 months, but evidence remains less robust than for established treatments.
